Lucid Diagnostics terminates ATM equity offering program after minimal sales

Lucid Diagnostics Inc.

Terminated ATM prospectus supplement effective March 4, 2025; no new sales without new filing.
Only $292,790 raised from 230,068 shares under the $6.5M facility since December 2022.
Sales Agreement with Cantor Fitzgerald remains in force but ATM sales are suspended.

item 8.01 item 9.01

Lucid Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-008974

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.